Alk-Abello AS (AKBLF)
24.60
0.00 (0.00%)
USD |
OTCM |
Sep 18, 16:00
Alk-Abello Revenue (Quarterly): 198.33M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 198.33M |
| March 31, 2024 | 196.78M |
| December 31, 2023 | 194.11M |
| September 30, 2023 | 162.10M |
| June 30, 2023 | 165.88M |
| March 31, 2023 | 177.96M |
| December 31, 2022 | 171.70M |
| September 30, 2022 | 143.78M |
| June 30, 2022 | 149.60M |
| March 31, 2022 | 174.23M |
| December 31, 2021 | 169.04M |
| September 30, 2021 | 147.13M |
| June 30, 2021 | 140.67M |
| March 31, 2021 | 165.51M |
| December 31, 2020 | 158.75M |
| September 30, 2020 | 121.28M |
| June 30, 2020 | 114.01M |
| March 31, 2020 | 141.14M |
| December 31, 2019 | 130.90M |
| September 30, 2019 | 110.09M |
| June 30, 2019 | 118.10M |
| March 31, 2019 | 131.95M |
| December 31, 2018 | 120.32M |
| September 30, 2018 | 103.08M |
| June 30, 2018 | 114.57M |
| Date | Value |
|---|---|
| March 31, 2018 | 124.06M |
| December 31, 2017 | 120.73M |
| September 30, 2017 | 104.46M |
| June 30, 2017 | 102.17M |
| March 31, 2017 | 113.03M |
| December 31, 2016 | 109.33M |
| September 30, 2016 | 94.47M |
| June 30, 2016 | 117.35M |
| March 31, 2016 | 125.38M |
| December 31, 2015 | 100.75M |
| September 30, 2015 | 99.33M |
| June 30, 2015 | 83.66M |
| March 31, 2015 | 98.45M |
| December 31, 2014 | 102.70M |
| September 30, 2014 | 92.82M |
| June 30, 2014 | 113.02M |
| March 31, 2014 | 125.56M |
| December 31, 2013 | 108.21M |
| September 30, 2013 | 90.46M |
| June 30, 2013 | 93.19M |
| March 31, 2013 | 107.95M |
| December 31, 2012 | 106.94M |
| September 30, 2012 | 102.07M |
| June 30, 2012 | 88.93M |
| March 31, 2012 | 107.03M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
110.09M
Minimum
Sep 2019
198.33M
Maximum
Jun 2024
156.65M
Average
160.42M
Median
Revenue (Quarterly) Benchmarks
| Genmab AS | 779.75M |
| Ascendis Pharma AS | 38.76M |
| Galecto Inc | -- |
| Evaxion Biotech AS | 0.154M |
| IO Biotech Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 29.01M |
| Total Expenses (Quarterly) | 160.22M |
| EPS Diluted (Quarterly) | 0.1299 |
| Enterprise Value | 5.412B |
| Gross Profit Margin (Quarterly) | 63.10% |
| Profit Margin (Quarterly) | 14.63% |
| Earnings Yield | 1.83% |
| Operating Earnings Yield | 2.40% |
| Normalized Earnings Yield | 1.828 |